Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PAUL A BENSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1174554364
CMS profile
53324
Location
BERKLEY, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$78,315.80

307 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 5 of 7; records 201–250 of 307 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PAUL A BENSON

NPI 1174554364 · CMS profile ID 53324

Allopathic & Osteopathic Physicians / Family Medicine

BERKLEY, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 7; records 201–250 of 307 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174554364?year=2021&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PAUL A BENSON, NPI 1174554364, CMS profile ID 53324. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 307 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174554364?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). PAUL A BENSON, NPI 1174554364, CMS profile ID 53324. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 7; records 201–250 of 307 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174554364?year=2021&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
PAUL A BENSON, NPI 1174554364, CMS profile ID 53324, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 7; records 201–250 of 307 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1174554364?year=2021&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

307 matching records · $78,315.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 307 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 307.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $0.2205/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162907 CMS
Gilead Sciences, Inc. $2.0405/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162909 CMS
Merck Sharp & Dohme Corporation $18.0305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848328049 CMS
Gilead Sciences, Inc. $1,660.0005/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852299 CMS
Gilead Sciences, Inc. $20.1905/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162905 CMS
Janssen Biotech, Inc. $17.7305/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954161 CMS
AbbVie Inc. $16.1705/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794039631 CMS
PFIZER INC. $21.0205/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833540333 CMS
Gilead Sciences, Inc. $1,040.0004/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852297 CMS
Janssen Biotech, Inc. $18.2804/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954143 CMS
Teva Pharmaceuticals USA, Inc. $0.8004/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839539171 CMS
Teva Pharmaceuticals USA, Inc. $11.1304/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839539173 CMS
ViiV Healthcare Company $2.7104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803243189 CMS
Gilead Sciences, Inc. $1.2104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162903 CMS
Gilead Sciences, Inc. $2.5204/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162899 CMS
Gilead Sciences, Inc. $8.4104/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162901 CMS
Gilead Sciences, Inc. $0.4504/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162897 CMS
Amarin Pharma Inc. $16.4804/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815426663 CMS
ViiV Healthcare Company $20.0304/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241687 CMS
Novo Nordisk Inc $12.2704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811061003 CMS
Gilead Sciences, Inc. $14.4804/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162895 CMS
Gilead Sciences, Inc. $91.9804/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162893 CMS
ViiV Healthcare Company $10.1204/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241065 CMS
ViiV Healthcare Company $10.9604/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803242479 CMS
ViiV Healthcare Company $4.1104/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803242535 CMS
Gilead Sciences, Inc. $1.7704/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162891 CMS
Janssen Biotech, Inc. $13.6104/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954155 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.0804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819864115 CMS
Teva Pharmaceuticals USA, Inc. $0.7704/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839539169 CMS
ViiV Healthcare Company $1,200.0004/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803242059 CMS
Teva Pharmaceuticals USA, Inc. $20.8204/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839539167 CMS
Gilead Sciences, Inc. $12.3904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162889 CMS
Kowa Pharmaceuticals America, Inc. $11.5304/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 805427409 CMS
Janssen Biotech, Inc. $18.8903/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954149 CMS
ViiV Healthcare Company $12.8003/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241711 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.1303/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819864113 CMS
ViiV Healthcare Company $7.1303/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803242361 CMS
Gilead Sciences, Inc. $0.1503/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162885 CMS
Gilead Sciences, Inc. $14.8403/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162887 CMS
ViiV Healthcare Company $14.7303/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241625 CMS
Antares Pharma, Inc. $13.1203/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827494131 CMS
Janssen Biotech, Inc. $36.8503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 787954151 CMS
Gilead Sciences, Inc. $1,040.0003/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845852295 CMS
Merck Sharp & Dohme Corporation $16.7703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848550613 CMS
Amarin Pharma Inc. $12.8103/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815163767 CMS
Novo Nordisk Inc $9.1603/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811100363 CMS
Gilead Sciences, Inc. $2.1703/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848162883 CMS
Merck Sharp & Dohme Corporation $11.6003/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848614231 CMS
ViiV Healthcare Company $120.7203/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803243837 CMS
ViiV Healthcare Company $20.1203/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 803241791 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $184,615.85 415
PY2020 $53,440.23 236
PY2021 $78,315.80 307
PY2022 $105,099.85 271
PY2023 $113,149.61 281
PY2024 $110,592.46 257
PY2025 $133,713.33 221

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $232,069.14 30
PY2024 Principal investigator $226,984.63 27
PY2023 Recipient $2,403.32 9
PY2023 Principal investigator $256,218.90 29
PY2022 Principal investigator $283,441.86 41
PY2021 Principal investigator $578,689.70 76
PY2020 Principal investigator $826,413.08 81
PY2019 Recipient $3,055.23 25
PY2019 Principal investigator $971,288.31 110

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Gilead Sciences, Inc. $1,509.00 12/16/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217399
Principal investigator 1 ViiV Healthcare Company $10,736.10 11/19/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315771
Principal investigator 1 ViiV Healthcare Company $1,206.00 11/19/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190318791
Principal investigator 1 Gilead Sciences, Inc. $1,372.00 11/18/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217390
Principal investigator 1 ViiV Healthcare Company $13,317.20 10/28/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315875
Principal investigator 1 Gilead Sciences, Inc. $7,325.00 10/21/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217382
Principal investigator 1 ViiV Healthcare Company $11,162.66 09/23/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315785
Principal investigator 1 Gilead Sciences, Inc. $3,040.00 09/16/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217373
Principal investigator 1 Gilead Sciences, Inc. $3,040.00 08/19/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217359
Principal investigator 1 ViiV Healthcare Company $15,261.92 08/15/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318793
Principal investigator 1 Gilead Sciences, Inc. $9,026.00 07/22/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217349
Principal investigator 1 ViiV Healthcare Company $11,265.57 07/17/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318789
Principal investigator 1 ViiV Healthcare Company $1,744.88 07/11/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190315879
Principal investigator 1 ViiV Healthcare Company $1,905.75 07/09/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315877
Principal investigator 1 Gilead Sciences, Inc. $2,482.00 06/17/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217338
Principal investigator 1 ViiV Healthcare Company $10,750.00 06/17/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
CAPTIVATE (CAB LA FOR PREP UTILIZATION OUTCOMES EXPERIENCE) No dispute reported 06/30/2026 1190315775
Principal investigator 1 ViiV Healthcare Company $17,408.34 06/13/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315783
Principal investigator 1 ViiV Healthcare Company $25,063.26 05/26/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315773
Principal investigator 1 Gilead Sciences, Inc. $3,180.00 05/20/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217330
Principal investigator 1 ViiV Healthcare Company $18,937.87 04/28/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315779
Principal investigator 1 Gilead Sciences, Inc. $8,626.00 04/22/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217322
Principal investigator 1 ViiV Healthcare Company $1,842.50 04/09/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315883
Principal investigator 1 ViiV Healthcare Company $11,551.62 04/09/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190318795
Principal investigator 1 ViiV Healthcare Company $2,784.60 03/21/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315781
Principal investigator 1 ViiV Healthcare Company $2,670.43 03/21/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318797
Principal investigator 1 Gilead Sciences, Inc. $3,040.00 03/18/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217314
Principal investigator 1 Gilead Sciences, Inc. $8,910.00 02/19/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217306
Principal investigator 1 ViiV Healthcare Company $2,490.75 01/29/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315777
Principal investigator 1 ViiV Healthcare Company $11,178.69 01/29/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER
A PHASE IIIB, MULTI-CENTER, NON-RANDOMIZED, PARALLEL-GROUP, OPEN-LABEL No dispute reported 06/30/2026 1190315881
Principal investigator 1 Gilead Sciences, Inc. $9,241.00 01/22/2025 Non-covered Recipient Entity
BE WELL MEDICAL CENTER PC
A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People >= 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection No dispute reported 06/30/2026 1229217293